Company intelligence / Profile preview

Mirror Biologics, Inc.

Ownership: Private
Development stage: Phase 2

Overview

Mirror Biologics is conducting multiple clinical trials including a Phase IIb open-label study in third-line metastatic colorectal cancer in the USA, a Phase II/III randomized controlled study in advanced/metastatic liver cancer in Thailand and Malaysia, and a Phase I/II trial in healthy adults over 65 to reverse immunosenescence. In January 2025, they entered a clinical collaboration with Merck KGaA to evaluate the combination of AlloStim and avelumab in fourth-line metastatic colorectal cancer.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Living immune cell therapyAllogeneic cell therapyImmunotherapy
Industry: Biotech

Drug pipeline

4 assets

allostim

3 more assets in the full pipeline.

Partnerships

Merck KGaA, Darmstadt, Germany

Beyond the preview

Go deeper on Mirror Biologics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mirror Biologics, Inc..